Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...

Genmab reported impressive earnings with significant revenue growth driven by its key products, despite rising expenses.

Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber has given his ...

Genmab AS (GMAB) reports a 29% revenue increase and strategic moves in its product pipeline, despite challenges in ...

Analysts' ratings for Genmab GMAB over the last quarter vary from bullish to bearish, as provided by 10 analysts. The following table provides a quick overview of their recent ratings ...

It has been roughly eight months since my last Genmab (GMAB) article, where I highlighted the company's robust pipeline progress, strategic partnerships, and a strong 2023 performance, led by ...

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...

Genmab (NASDAQ:GMAB) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Genmab to report an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...